Synapse

← Cancer Research Communications

Papers in Cancer Research Communications

Page 2 · newest first

  1. Patient-Level KRAS G12C Prevalence Among Hispanic/Latino and Non-Hispanic White Patients in Real-World Clinicogenomic CohortsCancer Research Communications · 2026
  2. A Phase 2 Study of Berzosertib in Combination with Carboplatin compared to Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate CancerCancer Research Communications · 2026
  3. CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid TumorsCancer Research Communications · 2026
  4. Impact of proton versus photon (chemo)radiation on circulating immune cells in head and neck cancerCancer Research Communications · 2026
  5. FGFR1 suppresses STING-mediated interferon response in endocrine therapy resistant breast cancerCancer Research Communications · 2026
  6. Inhibiting CXCR2 remodels the tumor microenvironment and blunts tumor progression and dissemination of high-grade serous carcinomaCancer Research Communications · 2026
  7. Neighborhood factors and treatment outcomes in pediatric acute lymphoblastic leukemia: A REDIAL Consortium reportCancer Research Communications · 2026
  8. Antitumor activity of novel transcriptional inhibitors ecubectedin and PM54 in soft tissue sarcoma patient-derived xenograftsCancer Research Communications · 2026
  9. Tumor Mutational Burden and Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients Treated with Neoadjuvant ChemotherapyCancer Research Communications · 2026
  10. Targeting PRMT5 inhibitor-induced adaptation in pancreatic cancer with the RBM39 degrader indisulamCancer Research Communications · 2026
  11. Early EGFR inhibition triggers actionable tumour and microenvironmental remodelling in lung cancerCancer Research Communications · 2026
  12. Mitochondrial tRNA-derived fragments as candidate metastasis-modifying RNACancer Research Communications · 2026
  13. Ex vivo tumor derived organoid pharmacotyping identifies personalized therapeutic options for biliary tract cancer patientsCancer Research Communications · 2026
  14. Survival of U.S. Military Service Members with Hodgkin Lymphoma by Post 9/11 Deployment StatusCancer Research Communications · 2026
  15. Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular AnalysesCancer Research Communications · 2026
  16. An Integrated Spatial Multi-Omics Workflow for Sequential RNA and Protein Profiling in FFPE Tumor TissueCancer Research Communications · 2026
  17. Febuxostat enhances the anti-tumor efficacy of 2-fluoroadenine and 5’-methylthioadenosine in MTAP-deleted cancerCancer Research Communications · 2026
  18. Combination AURKA and WEE1 inhibition exhibits efficacy in EGFR or pan-ERBB inhibitor resistant head and neck squamous cell carcinomaCancer Research Communications · 2026
  19. E3 Ubiquitin Ligase Mindbomb1 Is a Novel Negative Regulator of Tumor-Suppressive BMP SignalingCancer Research Communications · 2026
  20. Metabolic Syndrome, Component Burden, and Incident Gastric Cancer Risk: A Prospective Cohort Study in the UK BiobankCancer Research Communications · 2026
  21. Advancing Prostate Cancer Survivorship Through Transatlantic Consortium Science: The iCCaRE InitiativeCancer Research Communications · 2026
  22. Targeting wild-type NTRK in NTRK fusion negative lung cancer decreases brain metastasesCancer Research Communications · 2026
  23. Development and Validation of a Multimodal-Multitask Deep Learning Approach for Estimating Late Distant Recurrence Risk in HR–Positive Early Breast CancerCancer Research Communications · 2026
  24. Targeting the NAD+ salvage pathway blocks metabolic recovery and enhances β-lapachone toxicity in NQO1-expressing glioblastoma cellsCancer Research Communications · 2026
  25. Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non-Small Cell Lung Cancer: Insights From the EVOKE-01 StudyCancer Research Communications · 2026
  26. Glioblastoma subtypes exhibit distinct migration mechanics and immune responsesCancer Research Communications · 2026
  27. Schlafen 11 (SLFN11) is overexpressed in multiple myeloma and undergoes nucleolar translocation in response to bortezomibCancer Research Communications · 2026
  28. Acquisition of resistance to RAS inhibition is associated with the upregulation of macropinocytosis through both PI3K-dependent and -independent signalingCancer Research Communications · 2026
  29. Clinical validation of tissue and liquid companion diagnostics for BRAF V600E detection in non-small cell lung cancers from the PHAROS studyCancer Research Communications · 2026
  30. Tissue context shapes distinct premalignant outcomes in a HPV16 E6/E7-mutant Pik3ca transgenic mouse modelCancer Research Communications · 2026
  31. Association of Cumulative Proton Pump Inhibitor Use with Prostate Cancer Risk and Outcomes: A Population-Based Cohort StudyCancer Research Communications · 2026
  32. Comprehensive Profiling of Cell Surface Proteins in Testicular Germ Cell TumorsCancer Research Communications · 2026
  33. DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell EnrichmentCancer Research Communications · 2026
  34. A phase 1b study of chemo-immunotherapy with pegylated liposomal doxorubicin and Pembrolizumab in estrogen receptor positive metastatic breast cancerCancer Research Communications · 2026
  35. Chemotherapy Induced Neutropenia in Palestinian Patients with Solid Malignancies: Patient Characteristics, Severity Risk Factors & Management PatternsCancer Research Communications · 2026
  36. Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid TumorsCancer Research Communications · 2026
  37. Tumor-Associated Platelets Suppress T-Cell Function and Promote Immune Evasion in TNBC via the P-selectin/ P-selectin glycoprotein ligand-1 PathwayCancer Research Communications · 2026
  38. Development of Glypican-3-Targeting Antibody-Drug Conjugates for Hepatocellular Carcinoma TherapyCancer Research Communications · 2026
  39. BRAF inhibition-associated nuclear remodeling is linked to cancer-associated fibroblast activationCancer Research Communications · 2026
  40. Stromal cell subsets modulate T-cell infiltration in early breast cancerCancer Research Communications · 2026
  41. Tobemstomig, a novel bispecific antibody, preferentially blocks PD-1 and LAG-3 on CD8 TILs to expand stem-like T-cells for sustained tumor controlCancer Research Communications · 2026
  42. Predicting clinical sensitivities of PDGFRA exon 18 mutations to imatinib and avapritinib to optimize gastrointestinal stromal tumor treatmentCancer Research Communications · 2026
  43. Clinical evaluation of ex vivo expanded MUC1-specific peripheral blood T Cells for adoptive immunotherapy in relapsed/refractory multiple myelomaCancer Research Communications · 2026
  44. Peptide-reactive T cell response as a novel biomarker in head and neck cancer patients treated with anti-PD-1 antibodyCancer Research Communications · 2026
  45. Identifying and addressing barriers to live primary prostate cancer cell research in VeteransCancer Research Communications · 2026
  46. Downregulation of PIEZO1 activity promotes breast cancer cell survival under shear stress by modulating β-catenin and BCL2Cancer Research Communications · 2026
  47. Tumor CTR1 expression and systemic copper dynamics converge on a copper axis in high grade triple negative breast cancerCancer Research Communications · 2026
  48. Increasing burden of early-onset cancers: disentangling the contributions of changes in risk from demographic shiftsCancer Research Communications · 2026
  49. p97 Inhibition Synergistically Enhances Hypomethylating Therapy Through Targeting of PLK1 in Acute Myeloid LeukemiaCancer Research Communications · 2026
  50. CAR T-Cell Kinetics, Persistence and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-Cell ALL Treated with Obecabtagene Autoleucel in the FELIX StudyCancer Research Communications · 2026